These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25987174)

  • 1. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.
    Hollak CE; Weinreb NJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
    Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
    PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement for lysosomal diseases.
    Brady RO
    Annu Rev Med; 2006; 57():283-96. PubMed ID: 16409150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
    Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
    Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice.
    Sly WS
    Mo Med; 2004; 101(2):100-4. PubMed ID: 15119106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease.
    Crivaro AN; Mucci JM; Bondar CM; Ormazabal ME; Ceci R; Simonaro C; Rozenfeld PA
    PLoS One; 2019; 14(5):e0217780. PubMed ID: 31150494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
    Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
    Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword.
    Cohen IJ; Baris H; Mistry PK
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzyme Replacement Therapy for Lysosomal Storage Diseases.
    Kleppin S
    J Infus Nurs; 2020; 43(5):243-245. PubMed ID: 32881810
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the Next Barriers to Successful Therapy.
    Cohen IJ; Baris H; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
    [No Abstract]   [Full Text] [Related]  

  • 17. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.
    Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy.
    Ersoy M; Pişkinpaşa H
    J Pediatr Endocrinol Metab; 2022 Apr; 35(4):519-527. PubMed ID: 35245971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
    Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
    Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme reconstitution/replacement therapy for lysosomal storage diseases.
    Burrow TA; Hopkin RJ; Leslie ND; Tinkle BT; Grabowski GA
    Curr Opin Pediatr; 2007 Dec; 19(6):628-35. PubMed ID: 18025928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.